AstraZeneca Emphasizes Size As Key To Growth In Rx Market
Executive Summary
AstraZeneca is guiding investors in the pharmaceutical industry to consider size - both in terms of corporate resources and individual products - as the key to growth.
You may also be interested in...
Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.
AstraZeneca Nexium NDA Includes "On-Demand" Dosing
AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.
Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: